{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:48:58Z","timestamp":1778600938431,"version":"3.51.4"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Erythroblastic sarcoma (ES) (previously called chloroma or granulocytic sarcoma) are rare hematological neoplams characterized by the proliferation of myeloid blasts at extramedullary sites, and primarily involve the skin and soft tissue of middle-aged adults. ES may be concomitant with or secondary to myeloid neoplasms (mostly acute myeloid leukemia (AML)) or in isolated cases (de novo) without infiltration of the bone marrow by blasts. ES share cytogenetic and molecular abnormalities with AML, including <jats:italic>RUNX1T1<\/jats:italic> fusions. Some of these alterations seem to be correlated with particular sites of involvement. Herein, we report an isolated erythroblastic sarcoma with <jats:italic>NFIA::RUNX1T1<\/jats:italic> located in the central nervous system (CNS) of a 3-year-old boy. Recently, two pediatric cases of CNS MS with complete molecular characterization have been documented. Like the current case, they concerned infants (2 and 3\u00a0years-old) presenting a brain tumor (pineal involvement) with leptomeningeal dissemination. Both cases also harbored a <jats:italic>NFIA::RUNX1T3<\/jats:italic> fusion. ES constitutes a diagnostic challenge for neuropathologists because it does not express differentiation markers such as CD45, and may express CD99 which could be confused with CNS Ewing sarcoma. CD43 is the earliest pan-hematopoietic marker and CD45 is not expressed by erythroid lineage cells. E-cadherin (also a marker of erythroid precursors) and CD117 (expressed on the surface of erythroid lineage cells) constitute other immunhistochemical hallmarks of ES. The prognosis of patients with ES is similar to that of other patients with AML but de novo forms seem to have a poorer prognosis, like the current case. To conclude, pediatric ES with <jats:italic>NFIA::RUNX1T1\/3<\/jats:italic> fusions seem to have a tropism for the CNS and thus constitute a potential pitfall for neuropathologists. Due to the absence of circulating blasts and a DNA-methylation signature, the diagnosis must currently be made by highlighting the translocation and expression of erythroid markers.<\/jats:p>","DOI":"10.1186\/s40478-023-01708-5","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:02:18Z","timestamp":1705680138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CNS erythroblastic sarcoma: a potential emerging pediatric tumor type characterized by NFIA::RUNX1T1\/3 fusions"],"prefix":"10.1186","volume":"12","author":[{"given":"Arnault","family":"Tauzi\u00e8de-Espariat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucille","family":"Lew-Derivry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Abbou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"M\u00e9tais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Masliah-Planchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Mariet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Hasty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volodia","family":"Dangouloff-Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Boddaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Csanyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Aline-Fardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Lamaison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e9vin","family":"Beccaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Puget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"1708_CR1","unstructured":"WHO Classification of Tumours Editorial Board (2022) Haematolymphoid Tumours. Lyon (France): International Agency for Research on Cancer. WHO classification of tumours series, 5th Edn. Vol. 11"},{"issue":"8","key":"1708_CR2","doi-asserted-by":"publisher","first-page":"9156","DOI":"10.1002\/cam4.5654","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, Shu Y, Tang Y, Zhao S, Jia Y, Ji J et al (2023) RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification. Cancer Med 12(8):9156\u20139166","journal-title":"Cancer Med"},{"issue":"8","key":"1708_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348(8):694\u2013701","journal-title":"N Engl J Med"},{"issue":"23","key":"1708_CR4","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1182\/bloodadvances.2020002712","volume":"4","author":"KM Chisholm","year":"2020","unstructured":"Chisholm KM, Heerema-McKenney AE, Choi JK, Smith J, Ries RE, Hirsch BA et al (2020) Acute erythroid leukemia is enriched in NUP98 fusions: a report from the children\u2019s oncology group. Blood Adv 4(23):6000\u20136008","journal-title":"Blood Adv"},{"issue":"11","key":"1708_CR5","doi-asserted-by":"publisher","first-page":"E299","DOI":"10.1002\/ajh.25944","volume":"95","author":"Y Linnik","year":"2020","unstructured":"Linnik Y, Pastakia D, Dryden I, Head DR, Mason EF (2020) Primary central nervous system erythroid sarcoma with NFIA-CBFA2T3 translocation: a rare but distinct clinicopathologic entity. Am J Hematol 95(11):E299-301","journal-title":"Am J Hematol"},{"issue":"4","key":"1708_CR6","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.3324\/haematol.2019.231928","volume":"105","author":"H Liu","year":"2020","unstructured":"Liu H, Guinipero TL, Schieffer KM, Carter C, Colace S, Leonard JR et al (2020) De novo primary central nervous system pure erythroid leukemia\/sarcoma with t(1;16)(p31;q24) NFIA\/CBFA2T3 translocation. Haematologica Avr 105(4):e194\u2013e197","journal-title":"Haematologica Avr"},{"issue":"1","key":"1708_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ajcp\/aqaa216","volume":"156","author":"RL King","year":"2021","unstructured":"King RL, Siaghani PJ, Wong K, Edlefsen K, Shane L, Howard MT et al (2021) Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 translocation in an infant erythroblastic sarcoma. Am J Clin Pathol 156(1):129\u2013138","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"1708_CR8","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2006-02-003327","volume":"108","author":"MA Vodyanik","year":"2006","unstructured":"Vodyanik MA, Thomson JA, Leukosialin Slukvin II. (2006) (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 108(6):2095\u20132105","journal-title":"Blood"},{"issue":"5","key":"1708_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1309\/AJCP8M4QQTAZPGRP","volume":"141","author":"RS Ohgami","year":"2014","unstructured":"Ohgami RS, Chisholm KM, Ma L, Arber DA (2014) E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol Mai 141(5):656\u2013664","journal-title":"Am J Clin Pathol Mai"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01708-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01708-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01708-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:04:07Z","timestamp":1705680247000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01708-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1708"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01708-5","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital\u2019s local ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflict of interest directly related to the topic of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}